We present the case of a 56-year-old black woman with rheumatoid arthritis who developed worsening fatigue, fever, weight loss, and a vesiculobullous skin eruption while being treated with certolizumab pegol for her arthritis. Microscopic findings confirmed the diagnosis of a neutrophilic dermatosis.
T he neutrophilic dermatoses (ND) are a heterogeneous group of disorders that are overrepresented in patients with autoinfl ammatory syndromes such as rheumatoid arthritis (RA). Rheumatoid neutrophilic dermatosis (RND) is a rare subset that is specifi cally associated with RA and must be diff erentiated from its mimics, specifi cally infection and vasculitic syndromes. Perhaps the most diffi cult is diff erentiating RND from the other ND, which off er a continuous spectrum of clinical entities. RND typically manifests as symmetric erythematous papules, plaques, or, rarely, vesicles and bullae and tends to occur in patients with severe rheumatoid factor-positive RA. With a unique presentation, our patient exemplifi es that RND is on a continuum with other ND.
CASE DESCRIPTION
A 56-year-old African-American woman with a >10-year history of rheumatoid factor-positive RA and systemic hypertension was evaluated for a new rash. Her RA was severe and debilitating. Previous treatments included methotrexate, etanercept, adalimumab, rituximab, and tocilizumab. Several months prior to presentation, she began certolizumab pegol for her arthritis. During the treatment course she developed worsening fatigue and intermittent subjective fevers in addition to a painful rash on her thighs, elbow, hands, and feet. Th e rash was initially mild, but had a precipitous worsening leading to blister formation on the hands, feet, and thighs.
Examination revealed tender, purpuric vesicles on the palms and soles along with several hemorrhagic, tense bullae (Figure 1 ). In addition, there were purpuric papules on the lower legs and excoriated nodules on the thighs. Neither lymphadenopathy nor mucosal involvement was present. A complete blood count, complete metabolic panel, and serum protein electrophoresis were unremarkable except for mildly elevated serum creatinine at 1.51 mg/dL (reference range, 0.57-1.00). A lesional swab was negative for herpes simplex virus DNA by polymerase chain reaction. Lesional biopsies from a palmar vesicle and a thigh nodule demonstrated a diff use dermal infi ltrate of neutrophils, as well as focal hemorrhage (Figure 2a ). Leukocytoclasis and endothelial swelling were present, but there was no evidence of vasculitis (Figure 2b) . A lesional biopsy from the thigh for direct immunofl uorescence was negative. Topical clobetasol for 2 weeks provided mild relief of pain. A serum quantitative G-6-PD was normal at 314 U/10 12 red blood cells (reference range, 146-376), and the patient was commenced on oral dapsone at 100 mg daily. Th e lesions completely cleared within the next 4 weeks and have not recurred after 3 months of follow-up.
DISCUSSION
Sweet's syndrome (SS), pyoderma gangrenosum (PG), and erythema elevatum et diutinum (EED) are well-characterized ND associated with RA. RND was fi rst described in 1978 (1). Th is uncommon disease aff ects predominantly women (2:1) with severe and disabling rheumatoid factor-positive RA. erythematous, urticarial papules or plaques. A limited number of cases with tense vesiculobullous eruptions have been described (2) . Sites usually aff ected are the extensor aspect of joints, the dorsum of the hands, and forearms, with the palms, soles, and face less commonly aff ected.
A conclusive diagnosis rests upon both the clinical picture and the microscopic fi nding of diff use neutrophilic infi ltrates in the dermis along with exclusion of infection. Leukocytoclasis, endothelial swelling, and subepidermal edema are frequently noted, but vasculitis is not present. Tissue cultures are negative, as are immunofl uorescence studies. Th e complete etiopathogenesis of RND is not well understood. Continuous activation of neutrophils, coupled with extensive circulating immune complexes, may predispose the host to a severe neutrophilic cutaneous reaction (3). More recently, the role of interleukin-1 and tumor necrosis factor-α cytokines in the immunopathogenesis of ND have supported the classifi cation of ND as a spectrum of autoinfl ammatory syndromes (4) .
Th ere remain, however, some distinctive diff erences among the ND. RND, PG, and SS all share the presence of a neutrophilic reaction and the absence of vasculitis, whereas EED is notable for vasculitis. Chronic evolutive ulcerations characterize active PG lesions (5). SS and RND have numerous histologic similarities; thus, the clinical presentation may be the best tool to diff erentiate between the two (6). SS is characterized by an abrupt onset of tender, warm, erythematous plaques, papules, or nodules along with prodromal symptoms. Of note, certolizumab pegol has not been associated with ND to this point.
Th e distinguishing features that strongly favored RND in our patient were the acral vesicles and bullae as the primary lesion in her eruption. Th e bullous form of SS tends to present with fl accid hemorrhagic bullae that may have undermining, purpuric borders simulating early PG. When it appears localized to the dorsum hands, this form is more commonly associated with underlying malignancy (5) . In addition, our patient suff ered from debilitating RA, and although SS is associated with RA, RND is much more strongly associated with severe RA (6, 7) . RND, however, generally lacks prodromal symptoms, such as fever or malaise (6) . While the diagnosis is RND, the unique presentation in our patient exemplifi es that RND is on a continuum with other ND, such as SS. Th is off ers further support to the concept of "neutrophilic disease," fi rst described by Wallah et al as a syndrome representing a continuous spectrum of clinical entities (8) .
Resolution of lesions can occur without scarring, spontaneously, or can be associated with improvement of RA (9) . Treatment of RND is based on anecdotal evidence given the rarity of the condition. In general, most cases respond to either topical corticosteroids or systemic therapy. Methotrexate is commonly used for the articular manifestations, while dapsone is added to treat the cutaneous lesions. Our patient responded quickly and completely to 1 month of oral dapsone. Other treatment options have included hydroxychloroquine, colchicine, and cyclophosphamide. Recent insights into the immunological pathways have suggested that targeted biological therapies may be a treatment option (4). 
